Splash

Investors

We are committed to delivering our strategy and creating value for our shareholders.
Splash
Investors
Latest Results

Latest Results

We’re pleased to announce our latest results.

Download Results

Latest News

Latest Events

May 9 2022Regulatory
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022

Abstract supports ongoing Phase 3 program and planned NDA submission LONDON and RALEIGH, N.C., May 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the presentation of an abstract

May 4 2022Regulatory
Verona Pharma Announces May 2022 Investor Conference Participation

LONDON and RALEIGH, N.C., May 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces the company will participate in the following conferences in May 2022: LifeSci Partners Virtual Immunology & Inflammation Symposium Date: Tuesday, May 10 Time: 9:00 AM ET / 2:00

May 3 2022Regulatory
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 3 ENHANCE-2 trial on target to report top-line COPD data in Q3 2022 James Brady joined the Board as Non-Executive Director Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the

View all regulatory news
Splash

© Verona Pharma plc 2022. All rights reserved